Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17


Correction to: Buthionine sulfoximine sensitizes antihormone-resistant human breast cancer cells to estrogen-induced apoptosis.

Lewis-Wambi JS, Kim HR, Wambi C, Patel R, Pyle JR, Klein-Szanto AJ, Craig Jordan V.

Breast Cancer Res. 2018 Jun 14;20(1):57. doi: 10.1186/s13058-018-0986-y.


Mechanisms of endocrine resistance in breast cancer: an overview of the proposed roles of noncoding RNA.

Hayes EL, Lewis-Wambi JS.

Breast Cancer Res. 2015 Mar 17;17:40. doi: 10.1186/s13058-015-0542-y. Review.


Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time.

Ariazi EA, Cunliffe HE, Lewis-Wambi JS, Slifker MJ, Willis AL, Ramos P, Tapia C, Kim HR, Yerrum S, Sharma CG, Nicolas E, Balagurunathan Y, Ross EA, Jordan VC.

Proc Natl Acad Sci U S A. 2011 Nov 22;108(47):18879-86. doi: 10.1073/pnas.1115188108. Epub 2011 Oct 19.


The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor α and cyclin D1.

Lewis-Wambi JS, Kim H, Curpan R, Grigg R, Sarker MA, Jordan VC.

Mol Pharmacol. 2011 Oct;80(4):610-20. doi: 10.1124/mol.111.072249. Epub 2011 Jul 7.


The Conformation of the Estrogen Receptor Directs Estrogen-Induced Apoptosis in Breast Cancer: A Hypothesis.

Maximov P, Sengupta S, Lewis-Wambi JS, Kim HR, Curpan RF, Jordan VC.

Horm Mol Biol Clin Investig. 2011 Mar 1;5(1):27-34.


Antioxidant dietary supplementation in mice exposed to proton radiation attenuates expression of programmed cell death-associated genes.

Sanzari JK, Wambi C, Lewis-Wambi JS, Kennedy AR.

Radiat Res. 2011 May;175(5):650-6. doi: 10.1667/RR2330.1. Epub 2011 Mar 28.


Structure-function relationships of estrogenic triphenylethylenes related to endoxifen and 4-hydroxytamoxifen.

Maximov PY, Myers CB, Curpan RF, Lewis-Wambi JS, Jordan VC.

J Med Chem. 2010 Apr 22;53(8):3273-83. doi: 10.1021/jm901907u.


New hypotheses and opportunities in endocrine therapy: amplification of oestrogen-induced apoptosis.

Jordan VC, Lewis-Wambi JS, Patel RR, Kim H, Ariazi EA.

Breast. 2009 Oct;18 Suppl 3:S10-7. doi: 10.1016/S0960-9776(09)70266-8.


The Paradox of Oestradiol-Induced Breast Cancer Cell Growth and Apoptosis.

Maximov PY, Lewis-Wambi JS, Jordan VC.

Curr Signal Transduct Ther. 2009 May 1;4(2):88-102.


Protective effects of dietary antioxidants on proton total-body irradiation-mediated hematopoietic cell and animal survival.

Wambi CO, Sanzari JK, Sayers CM, Nuth M, Zhou Z, Davis J, Finnberg N, Lewis-Wambi JS, Ware JH, El-Deiry WS, Kennedy AR.

Radiat Res. 2009 Aug;172(2):175-86. doi: 10.1667/RR1708.1.


Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit?

Lewis-Wambi JS, Jordan VC.

Breast Cancer Res. 2009;11(3):206. doi: 10.1186/bcr2255. Epub 2009 May 29. Review.


Potential of l-buthionine sulfoximine to enhance the apoptotic action of estradiol to reverse acquired antihormonal resistance in metastatic breast cancer.

Lewis-Wambi JS, Swaby R, Kim H, Jordan VC.

J Steroid Biochem Mol Biol. 2009 Mar;114(1-2):33-9. doi: 10.1016/j.jsbmb.2008.12.016. Epub 2009 Jan 9.


By looking back we can see the way forward: enhancing the gains achieved with antihormone therapy.

Jordan VC, Patel R, Lewis-Wambi JS, Swaby RF.

Breast Cancer Res. 2008;10 Suppl 4:S16. doi: 10.1186/bcr2176. Epub 2008 Dec 18. No abstract available.


Buthionine sulfoximine sensitizes antihormone-resistant human breast cancer cells to estrogen-induced apoptosis.

Lewis-Wambi JS, Kim HR, Wambi C, Patel R, Pyle JR, Klein-Szanto AJ, Jordan VC.

Breast Cancer Res. 2008;10(6):R104. doi: 10.1186/bcr2208. Epub 2008 Dec 5. Erratum in: Breast Cancer Res. 2018 Jun 14;20(1):57.


Overexpression of CEACAM6 promotes migration and invasion of oestrogen-deprived breast cancer cells.

Lewis-Wambi JS, Cunliffe HE, Kim HR, Willis AL, Jordan VC.

Eur J Cancer. 2008 Aug;44(12):1770-9. doi: 10.1016/j.ejca.2008.05.016. Epub 2008 Jul 7.


Emerging principles for the development of resistance to antihormonal therapy: implications for the clinical utility of fulvestrant.

Ariazi EA, Lewis-Wambi JS, Gill SD, Pyle JR, Ariazi JL, Kim HR, Sharma CG, Cordera F, Shupp HA, Li T, Jordan VC.

J Steroid Biochem Mol Biol. 2006 Dec;102(1-5):128-38. Epub 2006 Nov 7.


Treatment of Postmenopausal Breast Cancer with Selective Estrogen Receptor Modulators (SERMs).

Lewis-Wambi JS, Jordan VC.

Breast Dis. 2005-2006;24:93-105. Review.


Supplemental Content

Loading ...
Support Center